STATEMENT: Patients For Affordable Drugs Now Applauds Chairs Maloney And Pallone For Investigating Biogen’s $56,000 Price Tag For Alzheimer’s Drug Aduhelm

WASHINGTON, D.C. — The following statement was issued by David Mitchell, cancer patient and founder of Patients For Affordable Drugs Now, in response to Chairs Maloney and Pallone’s announcement that the House Committee on Oversight and Reform and the House Committee on Energy and Commerce will investigate the approval and pricing of Biogen’s Alzheimer’s drug, Aduhelm:

“Once again, Chairs Maloney and Pallone are taking the lead in fighting for patients by investigating the ‘steep price of Biogen’s new Alzheimer’s drug Aduhelm and the process that led to its approval despite questions about the drug’s clinical benefit.’

“As patients, we are eager for new treatments for Alzheimer’s and other diseases with unmet need, but a price of $56,000 is simply, as the Alzheimer’s Association puts it, ‘unacceptable.’ Aduhelm is the poster child demonstrating the need for H.R. 3 and Medicare negotiation to curb the unilateral power of drug corporations to set prices as high as they think they can get away with. We are very grateful to Chairs Maloney and Pallone for their continued leadership in support of innovation patients need at prices we can afford.”

###